Biggest slice of revenue most likely attributed to Myeloma Fibrosis. The issue Incyte probably have concern with is that wherever the Jakavi pathway has some success, so will MSCs. But more to the point, MSCs are a cure whereas Jak Inhibitors are simply an ongoing treatment.
- Forums
- ASX - By Stock
- MSB
- Cell Therapy News/Articles
Cell Therapy News/Articles, page-16454
-
- There are more pages in this discussion • 1,332 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B |
Open | High | Low | Value | Volume |
99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 9996 | 99.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
99.5¢ | 18069 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 9996 | 0.990 |
2 | 32880 | 0.985 |
7 | 256748 | 0.980 |
3 | 27201 | 0.975 |
8 | 170032 | 0.970 |
Price($) | Vol. | No. |
---|---|---|
0.995 | 18069 | 3 |
1.000 | 26186 | 7 |
1.005 | 72373 | 3 |
1.010 | 82743 | 7 |
1.015 | 72242 | 5 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online